StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
18
This month
1
This year
1
Publishing Date
2024 - 04 - 07
1
2023 - 12 - 10
1
2023 - 12 - 09
1
2023 - 10 - 22
2
2023 - 07 - 29
1
2023 - 05 - 21
2
2023 - 04 - 09
1
2023 - 01 - 22
1
2022 - 12 - 11
1
2022 - 06 - 05
1
2022 - 04 - 09
1
2022 - 03 - 26
1
2022 - 02 - 26
2
2021 - 12 - 12
1
2021 - 12 - 11
1
Sector
Health technology
18
Tags
Asco
1
Cancer
2
Children
2
Copd
2
Diabetic
1
Dupixent
6
Global
1
Hiv
1
Immunotherapy
1
Macular
1
Market
1
N/a
18
One
2
Pancreatic
1
Phase 1
2
Phase 3
2
Positive
1
Potential
1
Regn5458
1
Report
1
Response
1
Results
6
Sanofi
1
Show
2
Therapeutics
1
Treatment
1
Trial
2
Urticaria
1
Year
2
Entities
Alnylam pharmaceuticals, inc.
1
Anika therapeutics inc.
1
Biontech se
1
Regeneron pharmaceuticals, inc.
10
Sanofi
18
Smith & nephew plc
1
Teva pharmaceutical industries ltd
3
Symbols
ABBV
7
ABT
4
ADBE
4
AHCO
4
ALDX
6
AMGN
6
AMPL
4
APLS
12
ARVL
15
BFI
6
BLRX
10
BNTX
5
BTAI
8
BY
6
BYND
6
CFFS
7
CHPT
5
CRL
12
DCGO
5
DFS
6
DISH
7
DOYU
7
DRVN
7
ENVX
9
EVA
6
EXPR
6
FATE
11
FE
6
FNCTF
18
FTCH
5
FULC
7
GDHG
6
HEPA
6
HII
11
IEP
10
IESC
9
IRTC
8
JNJ
17
KRNT
6
LPSN
6
LYV
7
MBLY
6
MIDD
6
MRCY
6
MS
17
MSS
9
NVCR
5
PLTR
7
REGN
10
SAP
5
SNY
18
SNYNF
18
SRNE
5
T
6
TAC
9
TGT
5
TIGR
10
TTCF
5
UPYY
12
VZ
7
Exchanges
Nasdaq
18
Crawled Date
2024 - 04 - 07
1
2023 - 12 - 10
1
2023 - 12 - 09
1
2023 - 10 - 22
2
2023 - 07 - 29
1
2023 - 05 - 21
2
2023 - 04 - 09
1
2023 - 01 - 22
1
2022 - 12 - 11
1
2022 - 06 - 05
1
2022 - 04 - 09
1
2022 - 03 - 26
1
2022 - 02 - 26
2
2021 - 12 - 12
1
2021 - 12 - 11
1
Crawled Time
00:00
104
00:20
20
01:00
84
02:00
49
03:00
34
04:00
27
04:20
14
05:00
68
06:00
103
07:00
120
08:00
91
08:20
4
09:00
92
10:00
88
11:00
218
12:00
258
12:15
9
12:20
70
12:30
41
13:00
221
13:15
8
13:20
59
13:30
58
14:00
188
14:15
12
14:20
48
14:30
58
15:00
154
15:15
6
15:20
50
15:30
66
16:00
184
16:20
26
17:00
189
18:00
148
19:00
120
20:00
118
20:20
18
21:00
159
22:00
132
23:00
102
Source
www.alnylam.com
1
www.globenewswire.com
12
www.prnewswire.com
5
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
symbols :
Snynf
crawled time :
20:20
save search
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Published:
2024-04-07
(Crawled : 20:20)
- globenewswire.com
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
1.68%
|
O:
2.24%
H:
0.0%
C:
-0.8%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
0.29%
|
O:
0.84%
H:
0.0%
C:
0.0%
REGN
|
News
|
$906.55
-0.09%
-0.08%
370K
|
Health Technology
|
-3.29%
|
O:
0.11%
H:
0.32%
C:
-0.07%
response
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
Published:
2023-12-10
(Crawled : 20:20)
- globenewswire.com
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
Email alert
Add to watchlist
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
Email alert
Add to watchlist
REGN
|
News
|
$906.55
-0.09%
-0.08%
370K
|
Health Technology
|
Email alert
Add to watchlist
trial
potential
New Hybrid Treatment Forces Cancer Cells to Starve
Published:
2023-12-09
(Crawled : 20:20)
- prnewswire.com
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
Email alert
Add to watchlist
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
Email alert
Add to watchlist
cancer
treatment
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
Published:
2023-10-22
(Crawled : 20:20)
- globenewswire.com
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
-8.72%
|
O:
0.73%
H:
0.0%
C:
-0.48%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-10.11%
|
O:
-0.69%
H:
0.0%
C:
0.0%
REGN
|
News
|
$906.55
-0.09%
-0.08%
370K
|
Health Technology
|
12.23%
|
O:
0.21%
H:
0.08%
C:
-1.81%
dupixent
children
year
one
results
show
Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
Published:
2023-10-22
(Crawled : 20:20)
- globenewswire.com
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
-8.72%
|
O:
0.73%
H:
0.0%
C:
-0.48%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-10.11%
|
O:
-0.69%
H:
0.0%
C:
0.0%
REGN
|
News
|
$906.55
-0.09%
-0.08%
370K
|
Health Technology
|
12.23%
|
O:
0.21%
H:
0.08%
C:
-1.81%
dupixent
children
year
one
results
show
Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS
Published:
2023-07-29
(Crawled : 20:20)
- globenewswire.com
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
Email alert
Add to watchlist
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
Email alert
Add to watchlist
REGN
|
News
|
$906.55
-0.09%
-0.08%
370K
|
Health Technology
|
Email alert
Add to watchlist
macular
trial
results
diabetic
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
Published:
2023-05-21
(Crawled : 20:20)
- globenewswire.com
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-14.06%
|
O:
-0.75%
H:
0.0%
C:
0.0%
REGN
|
News
|
$906.55
-0.09%
-0.08%
370K
|
Health Technology
|
19.53%
|
O:
0.44%
H:
0.75%
C:
-1.43%
dupixent
copd
results
Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine
Published:
2023-05-21
(Crawled : 20:20)
- globenewswire.com
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-14.06%
|
O:
-0.75%
H:
0.0%
C:
0.0%
REGN
|
News
|
$906.55
-0.09%
-0.08%
370K
|
Health Technology
|
19.53%
|
O:
0.44%
H:
0.75%
C:
-1.43%
dupixent
copd
results
Sobi to streamline nirsevimab contractual arrangements
Published:
2023-04-09
(Crawled : 20:20)
- prnewswire.com
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
-17.86%
|
O:
-2.7%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-15.72%
|
O:
-0.72%
H:
0.0%
C:
0.0%
Global Viscosupplementation Market Report 2022: Sector to Reach $6.27 Billion by 2028 at a 9.1% CAGR
Published:
2023-01-22
(Crawled : 20:20)
- prnewswire.com
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
Email alert
Add to watchlist
SNNUF
|
$12.39
-1.12%
2K
|
Health Technology
|
Email alert
Add to watchlist
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
Email alert
Add to watchlist
ANIK
|
$26.02
0.89%
0.88%
31K
|
Health Technology
|
Email alert
Add to watchlist
global
report
market
Press Release: Statement from Sanofi regarding Horizon Therapeutics plc (“Horizon”)
Published:
2022-12-11
(Crawled : 20:20)
- globenewswire.com
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
0.05%
|
O:
-2.34%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
0.64%
|
O:
0.02%
H:
0.0%
C:
0.0%
therapeutics
sanofi
Positive Phase 1 Data from mRNA-based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer presented at ASCO
Published:
2022-06-05
(Crawled : 20:20)
- globenewswire.com
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
Email alert
Add to watchlist
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
Email alert
Add to watchlist
BNTX
|
News
|
$88.18
-0.35%
-0.35%
280K
|
Health Technology
|
Email alert
Add to watchlist
immunotherapy
asco
positive
cancer
pancreatic
phase 1
$10.1 billion (€9.1 billion) pledged in new grants and loans as part of the Stand Up for Ukraine Event to support those who have had to flee their homes in Ukraine
Published:
2022-04-09
(Crawled : 20:20)
- prnewswire.com
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
Email alert
Add to watchlist
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
Email alert
Add to watchlist
Sanofi: Information concerning the total number of voting rights and shares – February 2022
Published:
2022-03-26
(Crawled : 20:20)
- globenewswire.com
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
Email alert
Add to watchlist
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
Email alert
Add to watchlist
Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria
Published:
2022-02-26
(Crawled : 20:20)
- globenewswire.com
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
Email alert
Add to watchlist
REGN
|
News
|
$906.55
-0.09%
-0.08%
370K
|
Health Technology
|
Email alert
Add to watchlist
TEVJF
|
News
|
$12.37
-24.22%
380
|
Health Technology
|
Email alert
Add to watchlist
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
Email alert
Add to watchlist
dupixent
urticaria
phase 3
hiv
Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis
Published:
2022-02-26
(Crawled : 20:20)
- globenewswire.com
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
Email alert
Add to watchlist
REGN
|
News
|
$906.55
-0.09%
-0.08%
370K
|
Health Technology
|
Email alert
Add to watchlist
TEVJF
|
News
|
$12.37
-24.22%
380
|
Health Technology
|
Email alert
Add to watchlist
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
Email alert
Add to watchlist
dupixent
New Results from ATLAS Phase 3 Program with Fitusiran Presented at ASH Annual Meeting 2021
Published:
2021-12-12
(Crawled : 20:20)
- alnylam.com
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
-2.92%
|
O:
3.01%
H:
0.28%
C:
-2.39%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-3.58%
|
O:
-0.42%
H:
0.0%
C:
0.0%
ALNY
|
$143.8
-1.55%
-1.58%
390K
|
Health Technology
|
-14.54%
|
O:
2.8%
H:
0.0%
C:
0.0%
results
phase 3
New REGN5458 (BCMAxCD3) Phase 1 Data Show 75% Response Rate at Highest Dose Levels Studied in Patients with Heavily Pretreated Multiple Myeloma
Published:
2021-12-11
(Crawled : 20:20)
- prnewswire.com
TEVJF
|
News
|
$12.37
-24.22%
380
|
Health Technology
|
Email alert
Add to watchlist
REGN
|
News
|
$906.55
-0.09%
-0.08%
370K
|
Health Technology
|
Email alert
Add to watchlist
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
Email alert
Add to watchlist
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
Email alert
Add to watchlist
regn5458
phase 1
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4323
183.85%
64.77%
220M
|
Consumer Services
BOF
|
$1.99
70.09%
41.21%
110M
|
ILAG
|
$0.51
6.03%
40.62%
1.7M
|
LICN
|
$0.941
68.04%
40.49%
15M
|
AMST
|
$3.31
65.5%
39.58%
70M
|
Technology Services
MTC
|
$3.615
61.38%
38.04%
9.3M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.45
12.5%
30.92%
320K
|
Health Services
MULN
|
News
|
$3.78
38.46%
27.78%
13M
|
Information
RILY
|
$29.86
37.48%
27.26%
12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.